MIRUM PHARMACEUTICALS INC

SVP Howe Jolanda’s recent buy‑sell of Mirum shares shows a “buy low, sell high” strategy amid strong Q4 momentum and a promising liver‑disease pipeline.

Insider sales spike at Mirum Pharma: CFO sells 6,001 shares near $100, hinting at short‑term risk but long‑term pipeline value.

CEO Peetz’s modest Mirum buy‑back and small sales reveal routine insider trading, not market shifts—insightful for investors eyeing future growth.

Howe Jolanda’s 2,721‑share sale shows routine portfolio management, not a warning—Mirum’s strong growth and insider buys keep confidence high.

Mirum Pharma insiders sell shares under a 10b‑5 plan – but the move signals liquidity needs, not poor prospects, as the stock stays strong and investors stay optimistic.

Mirum CFO’s disciplined block sales and low‑price buy‑backs reveal confidence in the company’s growth, signaling a strategic capital reallocation for investors to watch.

Fischer Laurent’s fresh buy of 3,977 Mirum shares signals management confidence as the company’s liver‑disease pipeline nears a breakthrough. Discover why this insider move matters for investors.

Mirum Pharmaceuticals insider buy: Director Saira Ramasastry purchases 2,000 shares, signaling cautious confidence amid volatile pricing and a 52‑week high decline.

Insider buying by Mirum Pharmaceuticals’ CFO signals confidence in cholestatic liver therapy pipeline—an optimistic outlook for investors.

Mirum Pharmaceuticals’ CMO’s 38% stake surge shows insider confidence, blending buy‑sell tactics with tax‑covering sales—insight for investors seeking growth prospects.